Jonas Dyhrfjeld-Johnsen

Jonas Dyhrfjeld-Johnsen

Company: Acousia Therapeutics

Job title: Chief Development Officer


Small Molecule, KCNQ4 Agonist ACOU085 for the Treatment & Prevention of Hearing Loss 4:15 pm

• The KCNQ4 ion channel, a biologically validated drug target, plays a key role in regulating excitability and homeostasis of cochlear sensorineural cells • This presentation highlights the otoprotective potential and development of the small molecule, clinical stage drug candidate ACOU085 for the treatment and prevention of hearing lossRead more

day: Day Two

Panel Discussion: De-risking the Early Development Process a Robust & Comprehensive Early Development Process is Essential to Minimize Setbacks Faced in the Clinic. 12:40 pm

This panel will be a structured conversation designed to answer key questions such as: • What metrics should we be measuring in the lab to predict good outcomes in the clinic? • Which animal models are the best predictors of success in the clinic? • How do we pick the right approaches, the right drugs,…Read more

day: Day One

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.